Aptus Capital Advisors’s Defiance Nasdaq Junior Biotechnology ETF IBBJ Stock Holding History

Aptus Capital Advisors’s Portfolio IBBJ Stock Details IBBJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,515	Closed	-$44K	–	598
2021 Q3	$44K	Hold	1,515	–	–	﹤0.01%	422
2021 Q2	$49K	Buy	+1,515	New	+$47.9K	﹤0.01%	430

Aptus Capital Advisors's IBBJ Position: Q4 2021 in Review

Aptus Capital Advisors sold out of Defiance Nasdaq Junior Biotechnology ETF (IBBJ) in Q4 2021, closing a stake of 1,515 shares — an estimated $44K sold.

Aptus Capital Advisors first reported a position in IBBJ in Q2 2021 and held it in 2 quarters. The position peaked at $49K in Q2 2021. 0 funds tracked by Wall St. Rank hold IBBJ as of Q4 2021.

Aptus Capital Advisors reported no remaining Defiance Nasdaq Junior Biotechnology ETF position as of Q4 2021 after selling out during the quarter.
Aptus Capital Advisors sold 1,515 Defiance Nasdaq Junior Biotechnology ETF shares in Q4 2021, an estimated $44K.
Aptus Capital Advisors first reported a position in Defiance Nasdaq Junior Biotechnology ETF in Q2 2021 and held it in 2 quarters.
Aptus Capital Advisors's Defiance Nasdaq Junior Biotechnology ETF position peaked at $49K in Q2 2021.
0 funds tracked by Wall St. Rank held Defiance Nasdaq Junior Biotechnology ETF as of Q4 2021.

Based on Aptus Capital Advisors's 13F filing for Q4 2021, filed 2 Feb 2022.